TICKERNERD
Menu
CAMPCAMPHealthcare · Biotechnology

CAMP Stock Forecast: CAMP4 Therapeutics Corp. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$4.25
−2.07% on the day

The 7 Wall Street analysts covering CAMP4 Therapeutics Corp. hold a median 12-month price target of $8.5 — +100.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$266.7M
Ticker Nerd rank
65 / 100
Median analyst target
$8.50
Analysts covering
7
Revenue$1.8M+18.8% y/y
Operating income−$13.4M
Net income−$33.5M
Free cash flow−$12.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.3%
1M
+1.9%
YTD
−30.7%
1Y
+52.9%
From 52W high
−40.4%
From 52W low
+86.4%
$2.28
$7.13
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CAMP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CAMP4 Therapeutics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
65 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
90
Growth
83
Momentum
78
Size
64
Value
47
Issuance
46
Revisions
46
Quality
34
Volatility
14

Accruals (90): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (14): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CAMP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CAMP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Oct 25Jan 26Apr 26Jul 26CAMPHigh $15.00Median $8.50Low $6.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $6.50Median $8.50High $15.00

The green dot is the last close — the median target sits +100.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
14 Aug 2026Piper SandlerReiteratesOverweight$12 → $15
16 June 2026JP MorganUpgradeOverweight—
16 June 2026JP MorganUpgradeOverweight$5.00 → $9.00
10 June 2026Chardan CapitalInitiatesBuy—
10 June 2026Chardan CapitalInitiatesBuy$6.50
14 Apr 2026Rodman & RenshawInitiatesBuy—
2 Apr 2026Leerink PartnersMaintainsOutperform—
2 Oct 2025Cantor FitzgeraldInitiatesOverweight—
16 Sept 2025JP MorganDowngradeNeutral—
15 Sept 2025Piper SandlerMaintainsOverweight—
27 May 2025WedbushInitiatesOutperform—
5 Nov 2024JP MorganInitiatesOverweight—
5 Nov 2024Leerink PartnersInitiatesOutperform—
5 Nov 2024Piper SandlerInitiatesOverweight—
5 Nov 2024William BlairInitiatesOutperform—
11 Jan 2024Goldman SachsMaintainsSell$0.35 → $0.30
9 Oct 2023Goldman SachsMaintainsSell$0.80 → $0.35
6 Oct 2023Craig-HallumDowngradeHold$0.50
6 Oct 2023Roth MKMMaintainsBuy$6.00 → $5.00
29 Aug 2023Roth MKMReiteratesBuy$6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CAMP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CAMP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, CAMP4 Therapeutics Corp. returned +52.9% against +17.5% for the S&P 500, dividends included.

CAMP vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Oct 25Jan 26Apr 26Jul 26CAMPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CAMP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

CAMP4 Therapeutics Corp. (CAMP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.6×

Cheaper than 84% of US stocks

Price / sales
63.3×

Cheaper than 5% of US stocks

Price / book
−356.9×

Cheaper than 99% of US stocks

EV / EBITDA
−3.6×

Cheaper than 76% of US stocks

Growth & margins
Revenue growth (YoY)
18.8%

Higher than 68% of US stocks

Earnings growth (YoY)
18.8%

Higher than 57% of US stocks

Gross margin
—
Operating margin
−752.1%

Higher than 6% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−545.9%

Higher than 3% of US stocks

Return on assets
−45.3%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

CAMP4 Therapeutics Corp. (CAMP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • CAMP4 Therapeutics Corp. has a market value of $266.7M and an enterprise value of $182.7M.

  • Revenue in the twelve months to 30 June 2026: $4.2M. The latest quarter grew 18.8% year on year.

  • Net income over the same four quarters: −$107.2M, a −2543.7% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$28.7M.

  • Shares outstanding: 51.9M.

  • Trailing P/E: −1.6×; forward P/E: −5.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • CAMP4 Therapeutics Corp. employs 48 people — $88K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

CAMP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CAMPCAMP4 Therapeutics Corp.$266.7M
65
PYXSPyxis Oncology, Inc.$267.7M
80
ALXOALX Oncology Holdings, Inc.$268.3M
62
FATEFate Therapeutics, Inc.$268.6M
94
TRDAEntrada Therapeutics, Inc.$264.0M
54
ACIUAC Immune SA$273.1M
35
FHTXFoghorn Therapeutics, Inc.$258.9M
69

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CAMP4 Therapeutics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CAMP news & analysis

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

GlobeNewsWire · 10 Sept 2026positive

CAMP4 Therapeutics received authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to conduct a Phase 1/2 human clinical trial of CMP-002 in patients with SYNGAP1-related disorder. This follows recent clearances to initiate first-in-human studies for the drug in Australia and Argentina.

Why it matters — This authorization expands CMP-002's regulatory approvals across multiple countries, advancing CAMP4's first-in-human clinical development program for a drug candidate targeting SYNGAP1-related disorder.

CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026

GlobeNewsWire · 8 Sept 2026neutral

CAMP4 Therapeutics announced it will host a virtual Analyst Day on September 28, 2026, to discuss CMP-002 for the treatment of SYNGAP1-related disorder. The event will feature presentations and Q&A led by executive leadership, with participation from patient advocates and a leading key opinion leader.

Why it matters — A CAMP watcher would care because the Analyst Day offers direct insight from company leadership and external experts into the progress and outlook of the CMP-002 program for SYNGAP1-related disorder.

CAMP4 to Participate in Upcoming Investor Conferences

GlobeNewsWire · 1 Sept 2026neutral

CAMP4 Therapeutics Corporation announced that it will participate in upcoming investor conferences. The company, a clinical-stage biopharmaceutical firm developing regulatory RNA-targeting therapeutics, made the announcement on September 1, 2026.

Why it matters — CAMP watchers may be interested in the company's participation in upcoming investor conferences, which could provide opportunities for management to present its pipeline and engage with investors.

CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 13 Aug 2026positive

CAMP4 Therapeutics reported a second-quarter loss of $0.22 per share, narrower than the $0.24 loss expected by the Zacks Consensus Estimate and an improvement from the $0.62 per share loss a year earlier. Revenue topped estimates in the quarter.

Why it matters — A CAMP watcher would note that the company narrowed its loss and beat both consensus and year-ago results, indicating improving financial performance.

CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights

GlobeNewsWire · 13 Aug 2026positive

CAMP4 reported its second quarter 2026 financial results and corporate highlights. The company secured regulatory clearance in two jurisdictions to begin its first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder, with trial initiation anticipated in the fourth quarter of this year.

Why it matters — A CAMP watcher would care because obtaining regulatory clearance marks a key step toward advancing CMP-002 into its first clinical trial, a significant milestone for the company's pipeline.

FAQ

Frequently asked questions about CAMP stock

What is the CAMP stock price forecast for 2026-2027?

The 7 Wall Street analysts covering CAMP4 Therapeutics Corp. have a median 12-month price target of $8.5, with estimates ranging from $6.5 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CAMP stock a buy right now?

Of the 7 analysts covering CAMP4 Therapeutics Corp., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CAMP4 Therapeutics Corp. 65 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CAMP?

As at 12 Sept 2026, CAMP4 Therapeutics Corp. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (90 of 100).

Will CAMP stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +100.0% from the last close, and Ticker Nerd's factor model ranks CAMP4 Therapeutics Corp. 65 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CAMP stock forecast for 2030?

No analyst covering CAMP4 Therapeutics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CAMP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6.5 to $15 over the next 12 months.

How has CAMP stock performed over the past year?

CAMP4 Therapeutics Corp. returned +52.9% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CAMP4 Therapeutics Corp. do?

Camp4 Therapeutics Corporation is a clinical-stage biopharmaceutical company focused on developing regulatory RNA-based therapeutics designed to increase gene expression and restore healthy protein levels. The company applies its ASO-based approach to address the underlying causes of genetic diseases by targeting regulatory RNA and aiming for precise control of protein production.

What is the latest news on CAMP?

The most recent item we track (GlobeNewsWire, 10 Sept 2026): "CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder". CAMP4 Therapeutics received authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to conduct a Phase 1/2 human clinical trial of CMP-002 in patients with SYNGAP1-related disorder. This follows recent clearances to initiate first-in-human studies for the drug in Australia and Argentina.

Company

About CAMP4 Therapeutics Corp.

Camp4 Therapeutics Corporation is a clinical-stage biopharmaceutical company focused on developing regulatory RNA-based therapeutics designed to increase gene expression and restore healthy protein levels. The company applies its ASO-based approach to address the underlying causes of genetic diseases by targeting regulatory RNA and aiming for precise control of protein production. Its work centers on disease areas where insufficient protein activity plays a key role, including disorders affecting the liver and central nervous system. Camp4 Therapeutics Corporation’s current pipeline includes product candidates for urea cycle disorders and SYNGAP1-related disorders, reflecting its focus on rare and genetically driven conditions. Based in Cambridge, Massachusetts, the company operates within the biotechnology sector and contributes to the broader effort to create targeted treatments for inherited diseases through RNA modulation.

CEO Mr. Joshua Mandel-Brehm · 48 employees · United States · https://www.camp4tx.com